On December 20, 2023, ZHB114 Injection, a new drug in Class 1 of therapeutic biologics originally developed by ZONHONBIO, which has completely independent intellectual property rights at home and abroad, was granted the Notice of Approval for Clinical Trial of Drugs by the NMPA. The approved indications are advanced malignant tumors.